25-Hydroxyvitamin D, APOE ε4 genotype and cognitive function: Findings from the 1958 British birth cohort

European Journal of Clinical Nutrition

Volumn 69, Issue 4, 2015, Pages 505-508

  Maddock, J ^a   Cavadino, A ^a   Power, C ^a   Hypponen E ^a,b  

^a UNIVERSITY COLLEGE LONDON   (United Kingdom)

^b UNIVERSITY OF SOUTH AUSTRALIA   (Australia)

Author keywords

[No Author keywords available]

Indexed keywords

25 HYDROXYVITAMIN D; APOLIPOPROTEIN E; APOLIPOPROTEIN E EPSILON 4; UNCLASSIFIED DRUG; APOLIPOPROTEIN E4; VITAMIN D;

ADULT; APOE EPSILON 4 GENE; ARTICLE; BLOOD SAMPLING; COHORT ANALYSIS; FEMALE; GENE; GENE INTERACTION; GENETIC ASSOCIATION; GENOTYPE; HUMAN; MALE; MEMORY DISORDER; UNITED KINGDOM; VITAMIN BLOOD LEVEL; WORD RECOGNITION; ALLELE; BLOOD; COGNITION; GENETICS; GREAT BRITAIN; MEMORY; MIDDLE AGED; NUTRITIONAL STATUS; STATISTICAL MODEL;

ALLELES; APOLIPOPROTEIN E4; COGNITION; COHORT STUDIES; FEMALE; GENOTYPE; GREAT BRITAIN; HUMANS; LINEAR MODELS; MALE; MEMORY; MIDDLE AGED; NUTRITIONAL STATUS; VITAMIN D;

EID: 84926419076     PISSN: 09543007     EISSN: 14765640     Source Type: Journal    
DOI: 10.1038/ejcn.2014.201     Document Type: Article

References (34)

1. Kramer AF, Bherer L, Colcombe SJ, Dong W, Greenough WT. Environmental influences on cognitive and brain plasticity during aging. J Gerontol A Biol Sci Med Sci 2004; 59: M940-M957
2. Lövdén M, Xu W, Wang H-X. Lifestyle change and the prevention of cognitive decline and dementia: what is the evidence? Curr Opin Psychiatry 2013; 26: 239-243
3. Balion C, Griffith LE, Strifler L, Henderson M, Patterson C, Heckman G, et al. Vitamin D, cognition, and dementia: a systematic review and meta-Analysis. Neurology 2012; 79: 1397-1405
4. Breitling LP, Perna L, Muller H, Raum E, Kliegel M, Brenner H. Vitamin D and cognitive functioning in the elderly population in Germany. Exp Gerontol 2012; 47: 122-127
5. Maddock J, Geoffroy M-C, Power C, Hyppönen E. 25-Hydroxyvitamin D and cognitive performance in mid-life. Br J Nutr 2014; 111: 904-914
6. Small BJ, Rosnick CB, Fratiglioni L, Backman L. Apolipoprotein E and cognitive performance: a meta-Analysis. Psychol Aging 2004; 19: 592-600
7. Egert S, Rimbach G, Huebbe P. Symposium on 'Metabolic flexibility in animal and human nutrition'Session IV: Nutritional compounds for optimised healthspan and life performance: ApoE genotype: from geographic distribution to function and responsiveness to dietary factors. Proc Nutr Soc 2012; 71: 410-424
8. Power C, Elliott J. Cohort profile: 1958 British birth cohort (National Child Development Study). Int J Epidemiol 2006; 35: 34-41
9. Atherton K, Fuller E, Shepherd P, Strachan DP, Power C. Loss and representativeness in a biomedical survey at age 45 years: 1958 British birth cohort. J Epidemiol Community Health 2008; 62: 216-223
10. Voight BF, Kang HM, Ding J, Palmer CD, Sidore C, Chines PS, et al. The metabochip, a custom genotyping array for genetic studies of metabolic, cardiovascular, and anthropometric traits. PLoS Genet 2012; 8: e1002793
11. Wadsworth M, Kuh D, Richards M, Hardy R. Cohort profile: The 1946 National Birth Cohort (MRC National Survey of Health and Development). Int J Epidemiol 2006; 35: 49-54
12. Llewellyn DJ, Lang IA, Langa KM, Huppert FA. Cognitive function and psychological well-being: findings from a population-based cohort. Age Ageing 2008; 37: 685-689
13. Hyppönen E, Turner S, Cumberland P, Power C, Gibb I. Serum 25-hydroxyvitamin D measurement in a large population survey with statistical harmonization of assay variation to an international standard. J Clin Endocrinol Metab 2007; 92: 4615-4622
14. Kirkwood BR, Sterne JA. Multiple regression. Medical Statistics. Blackwell Science Ltd: Oxford, 2003, pp 98-106
15. Goldberg DP, Cooper B, Eastwood MR, Kedward HB, Shepherd M. A standardized psychiatric interview for use in community surveys. Br J Prev Soc Med 1970; 24: 18-23
16. Lewis G, Pelosi AJ, Araya R, Dunn G. Measuring psychiatric disorder in the community: a standardized assessment for use by lay interviewers. Psychol Med 1992; 22: 465-486
17. Clayton D, Hills MStatistical Models in Epidemiology. Oxford University Press: Oxford, 1993
18. Eyles DW, Smith S, Kinobe R, Hewison M, McGrath JJ. Distribution of the vitamin D receptor and 1 alpha-hydroxylase in human brain. J Chem Neuroanat 2005; 29: 21-30
19. Eyles D, Brown J, Mackay-Sim A, McGrath J, Feron F. Vitamin D3 and brain development. Neuroscience 2003; 118: 641-653
20. Brown J, Bianco JI, McGrath JJ, Eyles DW. 1, 25-Dihydroxyvitamin D(3) induces nerve growth factor, promotes neurite outgrowth and inhibits mitosis in embryonic rat hippocampal neurons. Neurosci Lett 2003; 343: 139-143
21. Oermann E, Bidmon HJ, Witte OW, Zilles K. Effects of 1alpha, 25 dihydroxyvitamin D3 on the expression of HO-1 and GFAP in glial cells of the photothrombotically lesioned cerebral cortex. J Chem Neuroanat 2004; 28: 225-238
22. Brewer LD, Thibault V, Chen KC, Langub MC, Landfield PW, Porter NM. Vitamin D hormone confers neuroprotection in parallel with downregulation of L-Type calcium channel expression in hippocampal neurons. J Neurosci 2001; 21: 98-108
23. Moore M, Piazza A, McCartney Y, Lynch M. Evidence that vitamin D3 reverses agerelated inflammatory changes in the rat hippocampus. Biochem Soc Trans 2005; 33: 573-577
24. Bao BY, Ting HJ, Hsu JW, Lee YF. Protective role of 1 alpha, 25-dihydroxyvitamin D3 against oxidative stress in nonmalignant human prostate epithelial cells. Int J Cancer 2008; 122: 2699-2706
25. Dursun E, Gezen-Ak D, Yilmazer S. A novel perspective for Alzheimer's disease: vitamin D receptor suppression by Amyloid-β and preventing the Amyloid-β induced alterations by vitamin D in cortical neurons. J Alzheimers Dis 2011; 23: 207-219
26. Brewer LD, Porter NM, Kerr DS, Landfield PW, Thibault O. Chronic 1a, 25-(OH)2 vitamin D3 treatment reduces Ca2+-mediated hippocampal biomarkers of aging. Cell Calcium 2006; 40: 277-286
27. Wolf PA. Stroke risk profiles. Stroke 2009; 40: S73-S74
28. Barnard K, Colon-Emeric C. Extraskeletal effects of vitamin D in older adults: cardiovascular disease, mortality, mood, and cognition. Am J Geriatr Pharmacother 2010; 8: 4-33
29. Schipper HM. Apolipoprotein E: implications for AD neurobiology, epidemiology and risk assessment. Neurobiol Aging 2011; 32: 778-790
30. Lemire J. 1, 25-Dihydroxyvitamin D3-A hormone with immunomodulatory properties. Z Rheumatol 2000; 59: I24-I27
31. Zhang HL, Wu J, Zhu J. The role of apolipoprotein E in Guillain-Barré syndrome and experimental autoimmune neuritis. J Biomed Biotechnol 2010; e-pub ahead of print 16 February 2010; doi:10.1155/2010/357412
32. Maier SF. Bi-directional immune-brain communication: implications for understanding stress, pain, and cognition. Brain Behav Immun 2003; 17: 69-85
33. Jorm AF, Mather KA, Butterworth P, Anstey KJ, Christensen H, Easteal S. APOE genotype and cognitive functioning in a large age-stratified population sample. Neuropsychology 2007; 21: 1
34. Christensen H, Batterham PJ, Mackinnon AJ, Jorm AF, Mack HA, Mather KA, et al. The association of APOE genotype and cognitive decline in interaction with risk factors in a 65-69 year old community sample. BMC Geriatrics 2008; 8: 14